APELOA(000739)

Search documents
【华创证券】普洛药业深度研究报告:厚积薄发,已处于国内CDMO领军梯队
华创医药组公众平台· 2025-07-24 04:26
Core Viewpoint - Company has established itself as a leading player in the domestic CDMO sector, with strong global competitiveness in API, CDMO, and formulation businesses, and is expected to enter a new growth cycle as CDMO business enters an explosive phase and other segments return to long-term growth trajectories [3][6]. CDMO Business - The CDMO business is poised for explosive growth due to stable product quality, strong cost control, and efficient customer service, positioning the company as a core player in global innovative drug CDMO [3]. - Domestic innovation drug industry is thriving, with leading biotech companies emerging, which is expected to drive the company's rapid growth as domestic API projects commercialize [3]. - Long-term partnerships with overseas pharmaceutical giants are anticipated to contribute to sustained revenue and profit growth from both human and veterinary drug projects [3]. Formulation Business - The company is accelerating its "multi-variety" strategy leveraging its integrated API and formulation advantages, with an expected approval of over 15 new formulation products annually starting in 2026 [4]. - Investment in differentiated competition through higher technical barriers in modified new drugs is ongoing, utilizing advanced drug technology platforms to support long-term growth in the formulation business [4]. API Business - The API and intermediate business remains the foundation and largest component of the company's operations, with antibiotics expected to stabilize and rebound in prices from H2 2025 to 2026 [5]. - The veterinary drug sector is nearing a clearing phase, with potential for significant profit elasticity upon price recovery [5]. - The company continues to expand its slow disease API product pipeline, ensuring growth through capacity and technical advantages [5]. - The aesthetic medicine segment is expected to grow rapidly through diversified product offerings and deepening collaborations with leading clients [5].
趋势研判!2025年中国兽药原料药行业全景分析:预计市场规模约200亿元,市场集中度有望提升,市场竞争格局将得到改善[图]
Chan Ye Xin Xi Wang· 2025-07-22 01:27
Core Viewpoint - The veterinary raw material drug market in China is expected to grow significantly, with a projected market size of approximately 185.1 billion yuan in 2024 and around 200 billion yuan in 2025, driven by increased demand and favorable economic conditions [1][8]. Industry Characteristics and Classification - Veterinary raw material drugs are pharmacologically active substances used directly in the manufacture of veterinary drug formulations, characterized by specificity, regulatory requirements, and high technical barriers [2][4]. - They can be classified by chemical properties into synthetic raw materials, biotechnological raw materials, and natural extracts, and by usage into antimicrobial drugs, antiparasitic drugs, antipyretic analgesics, and diagnostic/treatment aids [4][5]. Current Development Status - The veterinary drug industry in China has rapidly developed, becoming a significant part of the global veterinary drug market, with a projected market size of approximately 600 billion yuan in 2024 and 635 billion yuan in 2025 [6][8]. Market Size and Growth - The veterinary raw material drug market is expected to see a growth from 185.1 billion yuan in 2024 to 200 billion yuan in 2025, reflecting a recovery in demand and controlled supply [8][10]. Market Segmentation - Antimicrobial drugs dominate the veterinary raw material drug market, holding an 84% market share, while antiparasitic drugs account for about 11% [10]. Industry Chain - The industry chain includes upstream components such as basic chemical raw materials and intermediates, midstream production of raw materials through chemical synthesis and fermentation, and downstream processing into veterinary drug formulations for livestock and pet healthcare [12]. Competitive Landscape - The veterinary raw material drug industry in China has a low concentration level, with major companies including Haisheng Pharmaceutical, Qihui Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, among others [14][16]. - The industry is experiencing a shift towards larger, more capable firms as regulatory standards improve, leading to a potential increase in market concentration [14]. Key Enterprises - Guobang Pharmaceutical reported a revenue of 1.831 billion yuan from animal health raw materials in 2024, with a gross margin of 18.86% [16]. - Haisheng Pharmaceutical achieved a revenue of 112 million yuan from raw materials in 2024, with a gross margin of 36.28% [18]. Technology Development Trends - The production of raw materials and intermediates requires significant investment in research and development to improve process technology and compete in higher-margin sectors [20].
普洛药业(000739):CDMO四问四答:华丽蜕变,跻身国内CDMO头部梯队
CMS· 2025-07-17 15:06
Investment Rating - The report maintains a "Strong Buy" investment rating for the company [2]. Core Views - The report highlights that the company has transformed into a leading player in the domestic CDMO sector, ranking in the top five of the "Top 20 CDMO Companies in China" for five consecutive years since 2020 [10][12]. - The company aims to expand its CDMO operational projects to 3,000 within 2-3 years, with 10-20 projects entering commercialization annually [10]. - The report emphasizes the company's comprehensive upgrades in both technical investment and manufacturing capabilities, which are expected to drive future growth [80]. Summary by Sections Section 1: Progress in CDMO Sector - The company has accumulated over 20 years of experience and has shifted from a traditional API company to a leading small molecule CDMO provider [10]. - The company has established a solid foundation for CDMO development through its extensive experience in chemical synthesis and production processes [11]. Section 2: R&D Capabilities - The company has significantly increased its R&D investment, expanding its CDMO R&D personnel from over 500 to an expected 1,000 in the next two years [32][41]. - It has established three major R&D centers globally and eight technical platforms to enhance its project acquisition and cost control capabilities [32][42]. Section 3: Manufacturing Advantages - The company maintains a strong manufacturing capability with a total chemical synthesis capacity of 11,000 m³ and a total biological fermentation capacity of 6,570 m³ [63]. - It has received multiple international certifications, including WHO, FDA, and EU EDQM, which enhances its service capabilities for global clients [63]. Section 4: Future Growth Potential - The company has signed confidentiality agreements with 572 domestic and international innovative pharmaceutical companies, indicating strong client engagement [66]. - The report notes that the company has 116 API projects, with 22 already commercialized and 15 in the validation stage, providing a robust growth pipeline [66]. Section 5: Financial Projections - The company is projected to achieve a net profit of 1.0 billion, 1.2 billion, and 1.5 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding PE ratios of 17, 14, and 11 [80].
普洛药业(000739) - 关于获得药品注册证书的公告
2025-07-03 11:30
关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 近日,普洛药业股份有限公司(以下简称"公司")全资子公司浙江巨泰药 业有限公司收到国家药品监督管理局(以下简称"药监局")签发的头孢克肟胶 囊《药品注册证书》。现将有关情况公告如下: 一、药品注册批准情况 1、产品名称:头孢克肟胶囊 2、剂型:胶囊剂 3、规格:0.1g(按 C16H15N5O7S2计) 证券代码:000739 证券简称:普洛药业 公告编号:2025-38 普洛药业股份有限公司 8、药品批准文号:国药准字 H20254638 9、审批结论:根据《中华人民共和国药品管理法》及有关规定,经审查, 本品符合药品注册的有关要求,批准注册,发给药品注册证书。 二、药品其他相关情况 本品适用于对头孢克肟敏感的链球菌属(肠球菌除外)、肺炎球菌、淋球菌、 卡他布兰汉球菌、大肠埃希菌、克雷伯杆菌属、沙雷菌属、变形杆菌属及流感嗜 血杆菌等引起的下列细菌感染性疾病:急性支气管炎、肺炎、慢性呼吸系统感染 疾病的继发感染、膀胱炎、肾盂肾炎、淋球菌性尿道炎、胆囊炎、胆管炎、中耳 炎、副鼻窦炎、猩红 ...
普洛药业:全资子公司浙江巨泰药业有限公司收到国家药品监督管理局签发的头孢克肟胶囊《药品注册证书》
news flash· 2025-07-03 11:24
Group 1 - The company, Prolog Pharma, announced that its wholly-owned subsidiary, Zhejiang Jutai Pharmaceutical Co., Ltd., received a drug registration certificate for Cefaclor capsules from the National Medical Products Administration [1] - The drug is indicated for bacterial infections caused by Streptococcus and other bacteria sensitive to Cefaclor [1] - The projected market size for the Chinese hospital market in 2024 is 455 million capsules, with a sales value of 387 million yuan [1] Group 2 - As of the announcement date, the total R&D investment for Cefaclor capsules amounted to 6.1 million yuan [1] - Obtaining the registration certificate is equivalent to passing the consistency evaluation of generic drug quality and efficacy, which qualifies the product for subsequent centralized procurement [1] - This development is expected to enhance the company's market competitiveness [1]
普洛药业(000739) - 关于回购公司股份的进展公告
2025-07-01 09:33
公司于2025年4月25日召开第九届董事会第十三次会议审议通过了《关于增 加回购股份资金来源的议案》,同意将本次回购股份的资金来源由"自有资金" 调整为"自有资金及金融机构借款"。除增加回购股份资金来源以外,公司本次 回购股份方案的其他内容未发生变化。具体内容详见公司于2025年4月26日在《证 券时报》和巨潮资讯网(http://www.cninfo.com.cn)上披露的《第九届董事会 第十三次会议决议公告》(公告编号:2025-26)、《关于增加回购股份资金来 源的公告》(公告编号:2025-27)。 根据《公司回购股份报告书》(公告编号:2025-06),若公司在本次回购 期限内发生派发红利、送红股、资本公积金转增股本等除权除息事项,自股价除 权除息之日起,按照中国证监会及深圳证券交易所的相关规定相应调整回购价格 上限。公司2024年度分红派息实施后,回购股份的价格上限由22元/股(含)调 整为21.65元/股(含),调整后的回购股份价格上限自2025年5月22日(除权除 息日)起生效。 证券代码:000739 证券简称:普洛药业 公告编号:2025-37 普洛药业股份有限公司 关于回购公司股份的进展 ...
6月30日晚间重要公告一览
Xi Niu Cai Jing· 2025-06-30 10:09
Group 1 - Taotao Automotive expects a net profit of 310 million to 360 million yuan for the first half of 2025, representing a year-on-year increase of 70.34% to 97.81% [1] - The company specializes in the research, production, and sales of all-terrain vehicles, electric golf carts, electric scooters, electric balance bikes, electric bicycles, and their accessories [1] - China Communications Construction Company plans to repurchase shares worth between 500 million to 1 billion yuan, with a maximum repurchase price of 13.58 yuan per share [1][2] Group 2 - Annoqi's subsidiary received a government subsidy of 1.65 million yuan, accounting for 34.77% of the company's latest audited net profit [2] - Annoqi focuses on the research, production, and sales of mid-to-high-end differentiated dyes [3] - Minfeng Special Paper announced the complete shutdown of its Nanhu plant, as its Haiyan plant is now capable of handling the production capacity [4] Group 3 - Aoto Electronics received a trademark registration certificate from Saudi Arabia, covering various electronic products [5] - Landi Group plans to acquire up to 20.1667% of the shares of Jujia Technology for a total price not exceeding 121 million yuan [6][7] - Lifan Pharmaceutical's Danpi phenol raw material drug has been approved for market launch, utilizing a new process that enhances efficiency and meets market demand [8] Group 4 - Shanghai Construction received a total of 548 million yuan in government subsidies, which accounts for 22.79% of the company's latest audited net profit [8] - Wanbangde's subsidiary received ethical approval for a key clinical trial of a new drug for Alzheimer's disease [8] - Prolo Pharmaceutical's subsidiary received approval for the market launch of a new raw material drug for liver cancer treatment [9] Group 5 - Chenguang New Materials received a government subsidy of 26 million yuan, representing 62.86% of the company's latest audited net profit [10] - Sanyou Medical's subsidiary received a government subsidy of 331,000 yuan, accounting for 28.86% of the company's latest audited net profit [11] - Weichai Heavy Machinery expects a net profit of 132 million to 151 million yuan for the first half of 2025, reflecting a year-on-year increase of 40% to 60% [12] Group 6 - Guanhao Biological announced the termination of its application for a specific stock issuance [13] - China Film plans to use up to 1.5 billion yuan of idle funds for cash management [14] - Aotai Biological intends to use up to 480 million yuan of idle raised funds for cash management [15] Group 7 - Helin Micro-Nano is planning to issue overseas shares and list on the Hong Kong Stock Exchange [17] - Jinpan Technology's vice president resigned due to personal health reasons [18] - Tongyi Zhong's chairman and general manager plan to reduce their shareholdings in the company [19] Group 8 - Naipu Mining signed an overseas contract worth 18.85 million USD [21] - Zhengye Technology completed an asset sale transaction worth 178 million yuan [23] - Lianxin Equipment won a bid for a project worth 157 million yuan from BOE [24] Group 9 - Smart Control plans to apply for a comprehensive credit line of up to 260 million yuan from banks [25] - Keyuan Pharmaceutical's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [27] - Meige Intelligent's H-share listing application materials have been received by the China Securities Regulatory Commission [29] Group 10 - Siwei Tuxin's subsidiary submitted an H-share listing application [32] - Metro Design's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [32] - Aeston submitted an application for H-share listing [34] Group 11 - Jiu Ri New Materials' shareholders plan to reduce their holdings by a total of 98,900 shares [34] - Yihua Tong's shareholder plans to reduce their holdings by up to 700,000 shares [35] - Xishanghai plans to distribute a cash dividend of 0.08 yuan per share [36] Group 12 - Zhejiang Natural plans to distribute a cash dividend of 1.97 yuan for every 10 shares [37] - Kouzi Jiao plans to distribute a cash dividend of 1.30 yuan per share [38] - Huitong Group plans to distribute a cash dividend of 0.023 yuan per share [40] Group 13 - Tongyong Co. plans to reduce its holdings by up to 0.31% of the company's shares [41] - China Shenhua plans to distribute a cash dividend of 2.26 yuan for every 10 shares [43] - Huangting International's executive director resigned due to personal reasons [45] Group 14 - Jinkai New Energy plans to distribute a cash dividend of 1 yuan for every 10 shares [46] - Heimu Dan plans to distribute a cash dividend of 0.041 yuan per share [47] - Feiyada plans to acquire all or part of the controlling stake in Chang Kong Gear [48]
普洛药业(000739) - 关于获得化学原料药上市申请批准通知书的公告
2025-06-30 08:30
证券代码:000739 证券简称:普洛药业 公告编号:2025-35 普洛药业股份有限公司 3、规格:15kg/桶 4、生产企业:浙江普洛康裕制药有限公司 5、通知书编号:2025YS00506 6、审批结论:根据《中华人民共和国药品管理法》及有关规定,经审查, 本品符合药品注册的有关要求,批准注册。 二、药品其他相关情况 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 近日,普洛药业股份有限公司(以下简称"公司")控股子公司浙江普洛康 裕制药有限公司收到国家药品监督管理局(以下简称"药监局")签发的甲苯磺 酸多纳非尼《化学原料药上市申请批准通知书》。现将有关情况公告如下: 一、药品注册批准情况 1、化学原料药名称:甲苯磺酸多纳非尼 2、申请事项:境内生产化学原料药上市申请 甲苯磺酸多纳非尼片(商品名:泽普生/Zepsun)是药监局批准上市的Ⅰ类 创新药,上市许可持有人为公司战略合作伙伴苏州泽璟生物制药股份有限公司 (以下简称"泽璟制药");用于治疗既往未接受过全身系统性治疗的不可切除 肝细胞癌,以及进展性、局部晚期 ...
普洛药业:甲苯磺酸多纳非尼原料药获上市批准
news flash· 2025-06-30 08:19
Core Viewpoint - Pro Pharmaceutical (000739) announced that its subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., received the approval notice for the listing application of Tofacitinib Tosylate from the National Medical Products Administration. This innovative Class I drug is intended for the treatment of unresectable hepatocellular carcinoma and refractory differentiated thyroid cancer. The approval is expected to have a positive impact on the company's future operations [1]. Group 1 - The drug Tofacitinib Tosylate is classified as an innovative Class I drug [1]. - The drug is specifically used for treating unresectable hepatocellular carcinoma and refractory differentiated thyroid cancer [1]. - The company has signed a research and production service contract with its partner, Suzhou Zejing Biopharmaceutical Co., Ltd., with the raw material ownership belonging to Zejing [1]. Group 2 - The approval from the National Medical Products Administration is anticipated to positively influence the company's future business operations [1].
普洛药业(000739) - 关于对下属公司担保的进展公告
2025-06-30 08:15
证券代码:000739 证券简称:普洛药业 公告编号:2025-36 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2025 年 6 月 10 日,普洛药业股份有限公司(以下简称"公司")与中 国银行股份有限公司东阳支行(以下简称"中国银行")签订《保证合同》(合 同编号:横店 2025 人保字 095 号),同意为公司全资子公司浙江普洛家园药业 有限公司(以下简称"家园药业")与中国银行签署的《商业汇票承兑协议》(合 同编号:横店 2025 人承字 095 号)中的 10,000 万元银行承兑汇票提供连带责任 保证,担保期限 6 个月。 6、2025 年 6 月 25 日,公司与中国银行签订《保证合同》(合同编号:横 店 2025 人保字 112 号),同意为公司控股子公司浙江普洛康裕制药有限公司(以 下简称"康裕制药")与中国银行签署的《商业汇票承兑协议》(合同编号:横 店 2025 人承字 112 号)中的 2,859 万元流动资金借款提供连带责任保证,担保 期限 6 个月。 7 ...